ArticleCancer cell international2026
NSUN6 overexpression promotes malignant phenotypes and predicts poor prognosis in clear cell renal cell carcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond mBiomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) lacks early clinical diagnostic markers, and advanced ccRCC has a poor prognosis. NSUN6, as a key component of m5C methyl-modifying enzymes, is abnormally expressed in several tumours and correlates with the prognosis. However, the expression and functional role of NSUN6 in ccRCC remain unknown.
methodsNSUN6 expression was analysed using TCGA data, RT-qPCR, and Western blot. In vitro migration and invasion assays were used to assess the effect of NSUN6 on the malignant function of ccRCC cells. ssGSEA, ESTIMATE, CIBERDORT, and TIMER databases were used to study the immune cell infiltration of NSUN6 in ccRCC. TIDE database, IPS scores, and GDSC database were used to assess the different NSUN6-expressing groups’ drug therapeutic effects.
resultsBioinformatics and clinical experiments demonstrated that the mRNA and protein expression of NSUN6 was significantly higher in ccRCC than in normal tissues. NSUN6 was an independent prognostic factor for ccRCC patients, and its high expression was significantly correlated with overall survival and disease-specific survival. In vitro experiments showed that NSUN6 promotes migration and invasion of ccRCC cells. NSUN6 was associated with immune infiltration of ccRCC and might affect the efficacy of immune and targeted therapies in patients.
conclusionHigh levels of NSUN6 were associated with poor prognosis in ccRCC and might promote tumour cell invasion and migration. In addition, NSUN6 played an important role in influencing the efficacy of tumour therapy. NSUN6 might further serve as a potential prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.